Literature DB >> 31104068

Recombinant Human Soluble Thrombomodulin in Patients With Sepsis-Associated Coagulopathy: Another Negative Sepsis Trial?

Tom van der Poll1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31104068     DOI： 10.1001/jama.2019.5792

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  End-point modification of recombinant thrombomodulin with enhanced stability and anticoagulant activity.

Authors:  Xia Liu; Mallorie Boron; Yu Zhao; Xue-Long Sun
Journal:  Eur J Pharm Sci       Date:  2019-09-09       Impact factor: 4.384

Review 2.  Targeting of G-protein coupled receptors in sepsis.

Authors:  Abdul Rehman; Noor Ul-Ain Baloch; John P Morrow; Pál Pacher; György Haskó
Journal:  Pharmacol Ther       Date:  2020-03-19       Impact factor: 12.310

3.  Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis.

Authors:  Kazuma Yamakawa; Jerrold H Levy; Toshiaki Iba
Journal:  Crit Care       Date:  2019-09-05       Impact factor: 9.097

4.  Efficacy and safety of human soluble thrombomodulin (ART-123) for treatment of patients in France with sepsis-associated coagulopathy: post hoc analysis of SCARLET.

Authors:  Bruno François; Maud Fiancette; Julie Helms; Emmanuelle Mercier; Jean-Baptiste Lascarrou; Toshihiko Kayanoki; Kosuke Tanaka; David Fineberg; Jean-Louis Vincent; Xavier Wittebole
Journal:  Ann Intensive Care       Date:  2021-03-31       Impact factor: 6.925

5.  Should we treat sepsis-induced DIC with anticoagulants?

Authors:  Yu Inata
Journal:  J Intensive Care       Date:  2020-02-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.